Drug Trial Radar · NCT07472647
SYS6090 Combination Therapy in Advanced Lung Cancer
Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
596
Planned (sponsor's estimate)
Start
Feb 28, 2026
Primary completion
Feb 28, 2029
Study completion Feb 28, 2030
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-cohort, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of SYS6090 injection in combination with chemotherapy or chemotherapy and bevacizumab or SYS6010 (an EGFR ADC) in participants with advanced lung cancer.
Conditions
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
Interventions
SYS6090 + pemetrexed + platinum-based chemotherapyDrug
In this group, participants will receive SYS6090 in combination with pemetrexed and platinum-based chemotherapy.
SYS6090 + paclitaxel + platinum-based chemotherapyDrug
In this group, participants will receive SYS6090 in combination with paclitaxel and platinum-based chemotherapy.
SYS6090 + docetaxelDrug
In this group, participants will receive SYS6090 in combination with docetaxel.
SYS6090 + pemetrexed + bevacizumab + platinum-based chemotherapyDrug
In this group, participants will receive SYS6090 in combination with pemetrexed, bevacizumab, and platinum-based chemotherapy
SYS6090 + SYS6010Drug
In this group, participants will receive SYS6090 and SYS6010.
SYS6090 + etoposide + platinum-based chemotherapyDrug
In this group, participants will receive SYS6090 in combination with etoposide and platinum-based chemotherapy.
SYS6090 + chemotherapy or other anticancer therapyDrug
In this group, participants will receive SYS6090 in combination with chemotherapy or other anticancer therapies.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicity (DLT) (Phase Ib)Time frame: Approximately 21 days.
- Adverse Events (AEs) (Phase Ib)Time frame: Up to 90 days after the last administration
- Objective response rate (ORR) (Phase II)Time frame: Through out the study (up to 2 years)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.